Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...agnosis...
...1. Stroke Risk in Patients With Nonvalvu...
Figure 1. Patterns of Atrial Fibrillatio...
Treatment
Treatment
...arin (A)30016...
...atran (B)300167...
...pixaban (B)3...
...varoxaban (B)300...
...he safety and efficacy of combining dabig...
..., Clopidogrel & Warfarin...
Adjusted-dose warfarin (target INR – 2.0-3.0)...
...herapy with aspirin is recommended for low-risk...
...high-risk patients with AF deemed unsuitable f...
...patients with ischemic stroke or TIA with p...
...ne is recommended. (A)300167...
...ination of clopidogrel plus aspirin carries a...
...igatran...
...atran is useful as an alternative to warfar...
...bigatran 150 mg twice daily is an effi...
...basis of pharmacokinetic data, the use of d...
...cause there are no data to support the use of dab...
Apixaba...
...mg twice daily is an efficacious alternative...
...ugh its safety and efficacy have not been...
...ice daily is a relatively safe and efficacious...
...ough its safety and efficacy have...
...pixaban should NOT be used if the CrCI i...
...ivaroxab...
...patients with nonvalvular AF who are a...
...th renal impairment and nonvalvular AF who...
...roxaban should NOT be used if the CrCI is...
...ts Recommended for Stroke PreventionaHa...
...re 2. Prevention of Stroke in Nonvalvula...